TY - JOUR T1 - Patient assessments of ease of use of Genuair® versus Aerolizer® and HandiHaler® JF - European Respiratory Journal JO - Eur Respir J VL - 38 IS - Suppl 55 SP - p3979 AU - Rainard Fuhr AU - Helgo Magnussen AU - David Singh AU - Gonzalo de Miquel AU - Cynthia Caracta AU - Esther Garcia Gil Y1 - 2011/09/01 UR - http://erj.ersjournals.com/content/38/Suppl_55/p3979.abstract N2 - Introduction: The Genuair®* inhaler, a multidose, dry powder inhaler, has been developed to provide reliable and effective delivery of inhaled medications including aclidinium bromide, which is in clinical development for the treatment of chronic obstructive pulmonary disease (COPD).Aim: To report data from two Phase II studies that included patient assessments of the convenience of Genuair® versus Aerolizer® and HandiHaler®, respectively.Methods: Both studies were randomised, double-blind, double-dummy, cross-over trials in patients with moderate to severe COPD. In the first study, 79 patients received treatment over seven-day periods via Genuair® and Aerolizer®. In the second study, 30 patients received treatment over 15-day periods via Genuair® and HandiHaler®. At the end of the studies, patients were asked to evaluate their impressions of inhaler conveniences.Results: Patient assessments of the different inhalers are presented in Table 1.Conclusions: Patient assessments of convenience were higher for the Genuair® inhaler versus the Aerolizer® or HandiHaler®.These studies were supported by Almirall S.A., Barcelona, Spain, and Forest Laboratories, Inc, New York, USA.*Genuair® is a registered trademark of Almirall S.A. ER -